AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30610875 — intervention group
Group type: COMPARATOR
Intervention: offline HD‐atDCS
Number of subjects: 9
Study 30610875 — intervention group
Group type: COMPARATOR
Intervention: sham
Number of subjects: 9
Study 26310877 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose nicotine dermal patches (n=90)
Number of subjects: 287
Study 26310877 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose nicotine dermal patches (n=132)
Number of subjects: 287
Study 26310877 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (n=65)
Number of subjects: 287
Study 26310877 — intervention group
Group type: EXPERIMENTAL
Intervention: First-generation antipsychotics (n=129)
Number of subjects: 287
Study 26310877 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation stage (n=97)
Number of subjects: 287
Study 26310877 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemplation stage (n=70)
Number of subjects: 287
Study 25367823 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite intervention consisting of education on recommended GWG according to IOM, application of personalised weight graph, formalised prescription of exercise and regular monitoring of GWG at every antenatal visit.
Number of subjects: 445
Study 25367823 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 445
Study 25367823 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite intervention
Number of subjects: 445
Study 23551662 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level light therapy (LLLT) device
Number of subjects: 40
Study 23551662 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 40
Study 23551662 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigator global assessment
Number of subjects: 40
Study 23551662 — intervention group
Group type: COMPARATOR
Intervention: Subject global assessment
Number of subjects: 40
Study 21481712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice (480 mL/day)
Number of subjects: 16
Study 21481712 — intervention group
Group type: COMPARATOR
Intervention: Placebo (480 mL/day)
Number of subjects: 16
Study 19461217 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (250 mg)
Number of subjects: 10
Study 19461217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 16831439 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate plus N-acetyl cysteine (50 mg twice per day and 1200 mg/d for 5 days)
Number of subjects: 804
Study 16831439 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate alone (with sugar powder)
Number of subjects: 804
Study 15105515 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised high-intensity progressive resistance training (PRT) for 12 weeks
Number of subjects: 42
Study 15105515 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised high-intensity progressive resistance training (PRT)
Number of subjects: 42
Study 15105515 — intervention group
Group type: COMPARATOR
Intervention: Upper extremity stretching (Control)
Number of subjects: 42
Study 15105515 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-based measures of function (both groups)
Number of subjects: 42
Study 12032753 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking
Number of subjects: 90
Study 12032753 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 90
Study 12032753 — intervention group
Group type: COMPARATOR
Intervention: Control (dietary counselling only)
Number of subjects: 90
Study 9579625 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-stage full-mouth disinfection (scaling and root planing of all pockets within 24 hours, application of chlorhexidine to all intra-oral niches, chlorhexidine mouth rinsing for 2 months)
Number of subjects: 24
Study 9579625 — intervention group
Group type: COMPARATOR
Intervention: Fractionated periodontal therapy (consecutive root planings per quadrant at a 1 to 2 week interval)
Number of subjects: 24
Study 9579625 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (1-stage full-mouth disinfection and fractionated periodontal therapy)
Number of subjects: 24
Study 9579625 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-stage full-mouth disinfection
Number of subjects: 24
Study 9579625 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-stage full-mouth disinfection and fractionated periodontal therapy
Number of subjects: 24
Study 8573224 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 12
Study 8573224 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 12
Study 2764538 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose enoxacin (600 mg)
Number of subjects: 154
Study 2764538 — intervention group
Group type: COMPARATOR
Intervention: 3-day treatment with enoxacin (200 mg twice a day)
Number of subjects: 154
Study 2764538 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 4 to 6 weeks
Number of subjects: 154
Study 793563 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride (double-blind trial)
Number of subjects: 15
Study 793563 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulants or tricyclic antidepressants (open trial)
Number of subjects: 15
Study 31212860 — intervention group
Group type: EXPERIMENTAL
Intervention: Green Space (GS) exposure
Number of subjects: 263
Study 31212860 — intervention group
Group type: COMPARATOR
Intervention: Randomized Controlled Trials (RCTs)
Number of subjects: 263
Study 31212860 — intervention group
Group type: COMPARATOR
Intervention: Qualitative subjective research
Number of subjects: 263
Study 28640436 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step irradiance schedule
Number of subjects: 141
Study 28640436 — intervention group
Group type: COMPARATOR
Intervention: Single-dose cold compress
Number of subjects: 141
Study 25853746 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-reduced red cells stored for 10 days or less (shorter-term storage group)
Number of subjects: 1098
Study 25853746 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-reduced red cells stored for 21 days or more (longer-term storage group)
Number of subjects: 1098
Study 23128421 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.3 mg/kg)
Number of subjects: 34
Study 23128421 — intervention group
Group type: COMPARATOR
Intervention: Rapid Sequence Induction (RSI) with thiopental 2‐3 mg/kg and remifentanil 1 mcg/kg
Number of subjects: 34
Study 21767799 — intervention group
Group type: EXPERIMENTAL
Intervention: Open benchmark quality circles (B-QC)
Number of subjects: 96
Study 21767799 — intervention group
Group type: COMPARATOR
Intervention: Traditional anonymous feedback quality circles (T-QC)
Number of subjects: 96
Study 21767799 — intervention group
Group type: EXPERIMENTAL
Intervention: Both B-QC and T-QC
Number of subjects: 96
Study 19815485 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-SPES 960 mg t.i.d.
Number of subjects: 38
Study 19815485 — intervention group
Group type: COMPARATOR
Intervention: DES 3 mg/day
Number of subjects: 38
Study 16707874 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF/SnF2 mouthwash after brushing
Number of subjects: 30
Study 16707874 — intervention group
Group type: COMPARATOR
Intervention: Omitting the post-brush water rinse
Number of subjects: 30
Study 14985223 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (daily supervised iron for 12 weeks)
Number of subjects: 523
Study 14985223 — intervention group
Group type: COMPARATOR
Intervention: Placebo iron (control group)
Number of subjects: 523
Study 11028575 — intervention group
Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 609
Study 11028575 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible care
Number of subjects: 609
Study 8831157 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured positive and negative bases of attitudes (Study 1)
Number of subjects: 0
Study 8831157 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated positive and negative bases of attitudes (Studies 2 and 3)
Number of subjects: 0
Study 8831157 — intervention group
Group type: EXPERIMENTAL
Intervention: Conflicting reactions (positive or negative)
Number of subjects: 0
Study 8831157 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant reactions
Number of subjects: 0
Study 8831157 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold of conflicting reactions
Number of subjects: 0
Study 1317133 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (up to 80 mg po daily)
Number of subjects: 20
Study 1317133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6328685 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine (Zantac)
Number of subjects: 88
Study 6328685 — intervention group
Group type: COMPARATOR
Intervention: Gelusil (antacid preparation)
Number of subjects: 88
Study 31322451 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent seasonal influenza vaccine (TIV)
Number of subjects: 1569
Study 31322451 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-vaccinated)
Number of subjects: 1569
Study 27423649 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion-tracking method of laparoscopic instruments using an optical pose tracker
Number of subjects: 44
Study 26048455 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 50mg plus dutasteride 3.5mg once daily for 18 months
Number of subjects: 127
Study 26048455 — intervention group
Group type: COMPARATOR
Intervention: Bicalutamide 50mg plus placebo
Number of subjects: 127
Study 23362889 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA ProSeal
Number of subjects: 116
Study 23362889 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 116
Study 21742541 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral zygopophyseal joint posteroanterior mobilisation
Number of subjects: 36
Study 21742541 — intervention group
Group type: EXPERIMENTAL
Intervention: Static posterior chain muscle stretch
Number of subjects: 36
Study 21742541 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment control
Number of subjects: 36
Study 20025366 — intervention group
Group type: EXPERIMENTAL
Intervention: Group motivational enhancement therapy (GMET)
Number of subjects: 206
Study 20025366 — intervention group
Group type: COMPARATOR
Intervention: Focus on Alcohol Concerns (FAC) education group
Number of subjects: 206
Study 20025366 — intervention group
Group type: COMPARATOR
Intervention: Alcohol information-only control group (AI)
Number of subjects: 206
Study 16431255 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 220
Study 16431255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 16324162 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 162
Study 16324162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 11057792 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol group (19 patients) treated to maintain 'supranormal' values of oxygen delivery
Number of subjects: 37
Study 11057792 — intervention group
Group type: COMPARATOR
Intervention: Control group (18 patients) treated to maintain normal values of oxygen delivery
Number of subjects: 37
Study 11057792 — intervention group
Group type: COMPARATOR
Intervention: Control group (18 patients)
Number of subjects: 37
Study 9390988 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional resistance training plus head‐extension exercise (ResX group)
Number of subjects: 0
Study 9390988 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional resistance training only
Number of subjects: 0
Study 9390988 — intervention group
Group type: COMPARATOR
Intervention: No resistance exercise (Control group)
Number of subjects: 0
Study 1589079 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia (forane)
Number of subjects: 35
Study 1589079 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptanalgesia (NLA)
Number of subjects: 35
Study 1589079 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 35
Study 3897471 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with Adriamycin for six months
Number of subjects: 156
Study 3897471 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (control group)
Number of subjects: 156
Study 3897471 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic irradiation (optional before randomization)
Number of subjects: 156
Study 3897471 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific cell types (leiomyosarcoma, homologous mixed mesodermal sarcoma, heterologous mixed mesodermal sarcoma)
Number of subjects: 156
Study 3897471 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with Adriamycin
Number of subjects: 156
Study 3277485 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 0.06 mg/kg po 90 min preoperatively
Number of subjects: 42
Study 3277485 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.1 mg/kg im plus scopolamine 0.006 mg/kg im 60 min preoperatively
Number of subjects: 42
Study 31584517 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-naive group
Number of subjects: 0
Study 31584517 — intervention group
Group type: COMPARATOR
Intervention: Previous treatment group
Number of subjects: 0
Study 29775166 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum foot insole
Number of subjects: 0
Study 29775166 — intervention group
Group type: COMPARATOR
Intervention: Control foot insole
Number of subjects: 0
Study 28630338 — intervention group
Group type: EXPERIMENTAL
Intervention: Values affirmation intervention
Number of subjects: 0
Study 26047319 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor allele (C) of rs3212227 in IL12(p40)
Number of subjects: 1729
Study 26047319 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor allele (A) of rs4073 in IL8
Number of subjects: 1729
Study 26047319 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor alleles of IL10 tagSNPs rs1800890 (A)
Number of subjects: 1729
Study 26047319 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor allele of IL10 tagSNP rs3021094 (C)
Number of subjects: 1729
Study 24172064 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-frame messages
Number of subjects: 261
Study 24172064 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-frame messages
Number of subjects: 261
Study 24172064 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to immunize during pregnancy
Number of subjects: 261
Study 24172064 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing the film 'Contagion'
Number of subjects: 261
Study 24172064 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 261
Study 21173438 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint evaluation of risk information formats (ARR, RRR, POL)
Number of subjects: 895
Study 21173438 — intervention group
Group type: EXPERIMENTAL
Intervention: Separate evaluation of risk information formats (ARR, RRR, POL)
Number of subjects: 895
Study 21173438 — intervention group
Group type: EXPERIMENTAL
Intervention: Separate evaluation of NNT
Number of subjects: 895
Study 21173438 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluability bias for risk information formats
Number of subjects: 895
Study 18332075 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (5 x 10(9) colony-forming units twice daily)
Number of subjects: 105
Study 18332075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 18332075 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Number of subjects: 105
Study 18332075 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG and Placebo
Number of subjects: 105
Study 17000820 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin gargle (350 mg)
Number of subjects: 60
Study 17000820 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine hydrochloride gargle (15 mL, 0.15%)
Number of subjects: 60
Study 17000820 — intervention group
Group type: COMPARATOR
Intervention: Mineral water (Control)
Number of subjects: 60
Study 17000820 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and benzydamine hydrochloride gargles
Number of subjects: 60
Study 14681960 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan mesilat (600 mg daily)
Number of subjects: 20
Study 14681960 — intervention group
Group type: COMPARATOR
Intervention: Other hypotensive medicines (control group)
Number of subjects: 20
Study 10763795 — intervention group
Group type: COMPARATOR
Intervention: Vinyl flooring
Number of subjects: 54
Study 10763795 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 54
Study 10763795 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional leg strengthening exercises
Number of subjects: 54
Study 8630590 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms twice daily
Number of subjects: 738
Study 8630590 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 100 micrograms twice daily
Number of subjects: 738
Study 8630590 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate 1,000 micrograms twice daily
Number of subjects: 738
Study 1361423 — intervention group
Group type: EXPERIMENTAL
Intervention: co‐trimoxazole for 3 days
Number of subjects: 117
Study 1361423 — intervention group
Group type: EXPERIMENTAL
Intervention: co‐trimoxazole for 7 days
Number of subjects: 117
Study 6428170 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (360 mg/d)
Number of subjects: 35
Study 6428170 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (180 mg/d)
Number of subjects: 35
Study 6428170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 31014469 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol intake (0.6 g/kg)
Number of subjects: 38
Study 29462230 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline cream 0.5%, 1.0%, or 1.5% applied topically once or twice daily for 28 days
Number of subjects: 356
Study 29462230 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline cream 1.5% applied twice daily
Number of subjects: 356
Study 29462230 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline cream 1.5% applied once daily
Number of subjects: 356
Study 29462230 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline cream (all concentrations)
Number of subjects: 356
Study 29462230 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 356
Study 27107460 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam (2000 mg ceftazidime plus 500 mg avibactam, administered via a 2-h intravenous infusion every 8 h for 5-21 days)
Number of subjects: 333
Study 27107460 — intervention group
Group type: COMPARATOR
Intervention: Best available therapy (mostly carbapenems, 163 (97%) of 168 patients received a carbapenem, 161 (96%) as monotherapy)
Number of subjects: 333
Study 27107460 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam
Number of subjects: 333
Study 27107460 — intervention group
Group type: COMPARATOR
Intervention: Best available therapy
Number of subjects: 333
Study 25185131 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 65
Study 25185131 — intervention group
Group type: COMPARATOR
Intervention: Midodrine
Number of subjects: 65
Study 22784612 — intervention group
Group type: EXPERIMENTAL
Intervention: Uzara® Lösung N (ULN)
Number of subjects: 18
Study 22784612 — intervention group
Group type: COMPARATOR
Intervention: Digoxin (1 mg, i.v.)
Number of subjects: 18
Study 22784612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 20440121 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired Set (PS) training
Number of subjects: 16
Study 20440121 — intervention group
Group type: COMPARATOR
Intervention: Traditional Set (TS) training
Number of subjects: 16
Study 20440121 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PS and TS training
Number of subjects: 16
Study 18326972 — intervention group
Group type: EXPERIMENTAL
Intervention: RASI/verapamil
Number of subjects: 0
Study 18326972 — intervention group
Group type: EXPERIMENTAL
Intervention: RASI/HCTZ to RASI/verapamil
Number of subjects: 0
Study 16307689 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 2099
Study 16307689 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 2099
Study 16307689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2099
Study 11907741 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine administration immediately prior to TACE (group A, n = 30)
Number of subjects: 113
Study 11907741 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine administration immediately after TACE (group B, n = 46)
Number of subjects: 113
Study 11907741 — intervention group
Group type: COMPARATOR
Intervention: No lidocaine administration (group C, n = 37)
Number of subjects: 113
Study 9972047 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiparasitic treatment (after two weeks)
Number of subjects: 40
Study 9972047 — intervention group
Group type: COMPARATOR
Intervention: Trichinella spiralis infection (before treatment)
Number of subjects: 40
Study 7992349 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron supplementation (200 mg ferrous sulphate daily)
Number of subjects: 0
Study 2738211 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivated condition
Number of subjects: 60
Study 2738211 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmotivated condition
Number of subjects: 60
Study 2738211 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed group
Number of subjects: 60
Study 2738211 — intervention group
Group type: COMPARATOR
Intervention: Nondepressed group
Number of subjects: 60
Study 30481760 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Cord Clamping (ICC)
Number of subjects: 101
Study 30481760 — intervention group
Group type: COMPARATOR
Intervention: Delayed Cord Clamping (DCC) for 30-60 s
Number of subjects: 101
Study 27846366 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive video gaming (IVG) using Nintendo Wii, 45 min per day, 6 days a week for 3 weeks
Number of subjects: 20
Study 27846366 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 20
Study 27846366 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive video gaming (IVG) using Nintendo Wii
Number of subjects: 20